Skip to main content
SpringerLink
Log in

Alcohol Septal Ablation for Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy

  • Secondary Prevention and Intervention (D. Steinberg, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To provide a contemporary review of data regarding patient selection and outcomes for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) undergoing septal reduction therapy with alcohol septal ablation (ASA).

Recent Findings

This review focuses on recent guideline updates from the USA and Europe, multiple recently published large multicenter, multinational registries of patients being treated with ASA, and a recent review of “real world” outcomes of ASA and surgical myectomy (SM) treated in hospitals in the USA.

Summary

Recent data have demonstrated that ASA is a safe procedure and is effective for the reduction of symptoms associated with obstructive HCM. Both short-and long-term outcomes after ASA appear similar to outcomes in patients undergoing SM and medical treatment. Outcomes in a real-world setting evaluating ASA and SM outside of high volume centers specializing in treatment of HCM show that ASA is increasing in use and that outcomes are fairly consistent across centers performing the procedure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, been highlighted as: • Of importance •• Of major importance

  1. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.; American Association for Thoracic Surgery.; American Society of Echocardiography.; American Society of Nuclear Cardiology.; Heart Failure Society of America.; Heart Rhythm Society.; Society for Cardiovascular Angiography and Interventions.; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2011;124(24):e783–831. doi:10.1161/CIR.0b013e318223e2bd.

    Article  PubMed  Google Scholar 

  2. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. doi:10.1093/eurheartj/ehu284.

    Article  PubMed  Google Scholar 

  3. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(8969):211–4.

    Article  CAS  PubMed  Google Scholar 

  4. Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, Naidu SS, Gade CL, Charitakis K, Singh HS, Feldman DN. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide inpatient database, 2003–2011. JAMA Cardiol. 2016;1(3):324–32. doi:10.1001/jamacardio.2016.0252.

    Article  PubMed  Google Scholar 

  5. Cooper RM, Binukrishnan SR, Shahzad A, Hasleton J, Sigwart U, Stables RH. Computed tomography angiography planning identifies the target vessel for optimum infarct location and improves clinical outcome in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. EuroIntervention. 2016; doi:10.4244/EIJ-D-15-00159.

    PubMed  Google Scholar 

  6. Sawaya FJ, Louvard Y, Spaziano M, Morice MC, Hage F, El-Khoury C, Roy A, Garot P, Hovasse T, Benamer H, Unterseeh T, Chevalier B, Champagne S, Piechaud JF, Blanchard D, Cormier B, Lefèvre T. Short and long-term outcomes of alcohol septal ablation with the trans-radial versus the trans-femoral approach: a single center-experience. Int J Cardiol. 2016;220:7–13. doi:10.1016/j.ijcard.2016.06.127.

    Article  PubMed  Google Scholar 

  7. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98(22):2415–21.

    Article  CAS  PubMed  Google Scholar 

  8. Veselka J, Lawrenz T, Stellbrink C, Zemanek D, Branny M, Januska J, Sitar J, Dimitrow P, Krejci J, Dabrowski M, Mizera S, Bartel T, Kuhn H. Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicenter and multinational study. Catheter Cardiovasc Interv. 2014;84(1):101–7. doi:10.1002/ccd.25236.

    Article  PubMed  Google Scholar 

  9. •• Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, Nielsen C, Leya F, Buergler JM, Rowe SK, Woo A, Maldonado YM, Spencer 3rd. WH. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter north American registry. J Am Coll Cardiol. 2011;58(22):2322–8. doi:10.1016/j.jacc.2011.06.073. This article reports on the largest North American experience of ASA

  10. Veselka J, Tomašov P, Zemánek D. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol. 2011;27(6):763–7. doi:10.1016/j.cjca.2011.09.001.

    Article  CAS  PubMed  Google Scholar 

  11. Liebregts M, Vriesendorp PA, Steggerda RC, Schinkel AF, Balt JC, Ten Cate FJ, Michels M, Ten Berg JM. Effect of alcohol dosage on long-term outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2016a;88(6):945–52. doi:10.1002/ccd.26448.

    Article  PubMed  Google Scholar 

  12. •• Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, Dabrowski M, Hansen PR, Almaas VM, Seggewiss H, Horstkotte D, Tomasov P, Adlova R, Bundgaard H, Steggerda R, Ten Berg J, Faber L. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the euro-ASA registry. Eur Heart J. 2016a;37(19):1517–23. doi:10.1093/eurheartj/ehv693. This study is the largest registry multicenter, multinational report of long term outcomes of ASA, establishing the safety and efficacy of ASA for the treatment of HCM with obstruction

    Article  PubMed  Google Scholar 

  13. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York heart association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation. 2002;106(4):454–9.

    Article  PubMed  Google Scholar 

  14. Liebregts M, Steggerda RC, Vriesendorp PA, van Velzen H, Schinkel AF, Willems R, van Cleemput J, van den Berg MP, Michels M, ten Berg JM. Long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly. JACC Cardiovasc Interv. 2016b;9(5):463–9. doi:10.1016/j.jcin.2015.11.036.

    Article  PubMed  Google Scholar 

  15. Veselka J, Tomašov P, Januška J, Krejčí J, Adlová R. Obstruction after alcohol septal ablation is associated with cardiovascular mortality events. Heart. 2016b; doi:10.1136/heartjnl-2016-309699.

    PubMed  Google Scholar 

  16. Rigopoulos AG, Daci S, Pfeiffer B, Papadopoulou K, Neugebauer A, Seggewiss H. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2016;105(11):953–61.

    Article  CAS  PubMed  Google Scholar 

  17. Schuller JL, Zipse MM, Krantz MJ, Blaker B, Salcedo E, Groves BM, Messenger JC, Beaty B, Sauer WH. Incidence and predictors of late complete heart block after alcohol septal ablation treatment of hypertrophic obstructive cardiomyopathy. J Interv Cardiol. 2015;28(1):90–7. doi:10.1111/joic.12178.

    Article  PubMed  Google Scholar 

  18. Singh K, Qutub M, Carson K, Hibbert B, Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2016;88(1):107–15. doi:10.1002/ccd.26293.

    Article  PubMed  Google Scholar 

  19. • Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3(11):896–905. doi:10.1016/j.jchf.2015.06.011. Largest meta-analysis reported in the literature comparing SM to ASA on long term outcomes

    Article  PubMed  Google Scholar 

  20. Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AF, Willems R, Ten Cate FJ, van Cleemput J, Ten Berg JM, Michels M. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2014;2(6):630–6. doi:10.1016/j.jchf.2014.06.012.

    Article  PubMed  Google Scholar 

  21. Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012;143:303–9. doi:10.1016/j.jtcvs.2011.10.059.

    Article  PubMed  Google Scholar 

  22. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi F, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik JA, Nishimura RA. Long-term effect of surgical myectomy on survival in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470–6.

    Article  PubMed  Google Scholar 

  23. Sorajja P, Nishimura RA, Gersh BJ, Dearani JA, Hodge DO, Wiste HJ, Ommen SR. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:234–41. doi:10.1016/j.jacc.2009.01.079.

    Article  PubMed  Google Scholar 

  24. Guerrero M, Wang DD, O'Neill W. Percutaneous alcohol septal ablation to acutely reduce left ventricular outflow tract obstruction induced by transcatheter mitral valve replacement. Catheter Cardiovasc Interv. 2016;88(6):E191–7. doi:10.1002/ccd.26649.

    Article  PubMed  Google Scholar 

  25. Sorajja P, Booker JD, Rihal CS. Alcohol septal ablation after transaortic valve implantation: the dynamic nature of left outflow tract obstruction. Catheter Cardiovasc Interv. 2013;81(2):387–91. doi:10.1002/ccd.23454.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Cardiac Catheterization Laboratories, University of Colorado School of Medicine, 12401 E. 17th Avenue, Box B132, Aurora, CO, 80045, USA

    John C. Messenger

  2. Division of Cardiology, Echocardiography Laboratory, Hypertrophic Obstructive Cardiomyopathy Clinic, University of Colorado School of Medicine, Aurora, CO, 80045, USA

    Ernesto E. Salcedo

Authors
  1. John C. Messenger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernesto E. Salcedo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John C. Messenger.

Ethics declarations

Conflict of Interest

Drs Messenger and Salcedo declare that they have no conflict of interest with this article’s content.

Dr. Salcedo does report research and consulting support from Philips Medical Systems.

Human and Animal Rights and Informed Consent

All reported studies with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

This article is part of the Topical Collection on Secondary Prevention and Intervention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Messenger, J.C., Salcedo, E.E. Alcohol Septal Ablation for Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy. Curr Cardiovasc Risk Rep 11, 15 (2017). https://doi.org/10.1007/s12170-017-0540-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-017-0540-y

Keywords

Search

Navigation